Over the past 2 decades, significant advances have been made in managing chronic kidney disease (CKD) in patients with type 2 diabetes (T2D), with therapies such as renin-angiotensin system (RAS) inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors proving effective in slowing CKD progression.1 Here, SLC5A2 is linked to chronic kidney disease.